CVS Health and its embattled Omnicare unit have agreed to pay $440 million to the Department of Justice to satisfy a nearly $950 million judgment against the company as part of an ongoing fraud case.
In April 2025, a federal jury ruled that Omnicare submitted more than 3.3 million fraudulent prescription claims between 2010 and 2018, earning $135.6 million in overpayments as a result. Then, in July 2025, a judge ordered Omnicare to pay $948.8 million in fees and damages as part of the case.
In the new court docs, CVS said that it has agreed to make an initial $130 million payment within 14 days of the agreement's effective date. The remaining $310 million must be paid out by March 15, 2028.
The agreement with DOJ is contingent on the closure of Omnicare's sale to GenieRx Holdings, according to the filing. As it navigated the legal fallout of the False Claims Act case, Omnicare filed for bankruptcy in September 2025, and CVS announced plans to sell to GenieRx in May of this year.
"Together, the Agreements establish the framework for the Debtors to confirm consensual chapter 11 plans, eliminate the need for protracted and expensive litigation, resolve the treatment of DOJ’s and CVS’ claims, and provide the best chance that all other general unsecured claims will be paid in full," per the court filing.
A spokesperson for CVS Health said in a statement to Fierce Healthcare that "agreements are not an admission of liability or wrongdoing and were agreed upon to avoid the time...
[Sportschosun Jang Jong-ho] A total of 34.789 billion won in false National Health Insurance claims was detected at 839 health care institutions over the past four years (2022-2025). According to d...